Adrestia Therapeutics

Adrestia Therapeutics is owned by Insmed.

Insmed is one of the...

• Russell 3000.

Insmed is a company listed under the stock ticker INSM (US).

Insmed has a direct presence in 2 countries.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

View the org chart displaying its 2 main executives

Most searched biographies at Adrestia Therapeutics

• Joanna Green, Director
• Will Lewis, Chairman of the Board

Create your alert
to follow the executive moves at Adrestia Therapeutics.

Insmed has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Histogen has filed for bankruptcy protection  (posted on April 19 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).

Popular contacts in Biotechnology

• Vik Bajaj - Director at Interline Therapeutics
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Adrestia Therapeutics

• Huntington’s disease progression stopped in cell study by University of Cambridge and UCL researchers

Social media about Adrestia Therapeutics

• Adrestia Therapeutics on Wikipedia, Google News & Yahoo Finance
• Adrestia Therapeutics on LinkedIn, Twitter & YouTube

Call Adrestia Therapeutics at +44 122...

View the org chart

Register to receive your alert

Report an error